

Samantha Fraser-Bell Franzco

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/309479/samantha-fraser-bell-franzco-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86
papers

3,054
citations

29
h-index

54
g-index

97
ext. papers

3,592
ext. citations

3.7
avg, IF

5
L-index

#	Paper	IF	Citations
86	Optical coherence tomography angiography findings of fellow eye of proliferative macular telangiectasia type 2: Long term study. <i>European Journal of Ophthalmology</i> , 2021 , 31, 1933-1939	1.9	1
85	Optical-coherence tomography angiography and ultrawide-field angiography findings in eyes with refractory macular edema secondary to retinal vein occlusion switched to aflibercept: A subanalysis from a 48-week prospective study.. <i>Taiwan Journal of Ophthalmology</i> , 2021 , 11, 352-358	1.4	
84	Patient-reported outcomes from a phase IV study of aflibercept in patients with refractory retinal vein occlusions. <i>Taiwan Journal of Ophthalmology</i> , 2021 , 11, 244-250	1.4	0
83	Subclinical subretinal fluid detectable only by optical coherence tomography in choroidal naevi-the SON study. <i>Eye</i> , 2021 , 35, 2038-2044	4.4	
82	Effect of intravitreal injection speed on acute rise in intraocular pressure. The SPEED IOP study. <i>Clinical and Experimental Ophthalmology</i> , 2021 , 49, 519-521	2.4	
81	Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. <i>Eye</i> , 2021 ,	4.4	1
80	Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater. <i>Clinical and Experimental Ophthalmology</i> , 2021 , 49, 570-578	2.4	1
79	Age-related macular degeneration masqueraders: From the obvious to the obscure. <i>Survey of Ophthalmology</i> , 2021 , 66, 153-182	6.1	1
78	Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes. <i>Ophthalmology Retina</i> , 2021 , 5, 511-518	3.8	5
77	GRADING of functional and anatomical response to DEXAMETHASONE implant in patients with Diabetic Macular Edema: GRADE-DME Study. <i>Scientific Reports</i> , 2021 , 11, 4738	4.9	1
76	Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry. <i>British Journal of Ophthalmology</i> , 2021 ,	5.5	1
75	Asymptomatic occlusive retinal vasculitis in newly diagnosed active tuberculosis. <i>Respiratory Medicine Case Reports</i> , 2021 , 33, 101456	1.2	
74	Using Lean Six Sigma techniques to improve efficiency in outpatient ophthalmology clinics. <i>BMC Health Services Research</i> , 2021 , 21, 38	2.9	2
73	Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: Data from the Fight Retinal Blindness! Registry. <i>Clinical and Experimental Ophthalmology</i> , 2020 , 48, 802-812	2.4	2
72	Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study. <i>Ophthalmology</i> , 2020 , 127, 1663-1673	7.3	10
71	Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity. <i>Acta Ophthalmologica</i> , 2020 , 98, e801-e806	3.7	2
70	One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation. <i>British Journal of Ophthalmology</i> , 2020 , 104, 678-683	5.5	3

69	Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion. <i>Asia-Pacific Journal of Ophthalmology</i> , 2020 , 9, 48-53	3.5	0
68	Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry. <i>Ophthalmology</i> , 2020 , 127, 608-615	7.3	17
67	Preclinical and clinical studies of photobiomodulation therapy for macular oedema. <i>Diabetologia</i> , 2020 , 63, 1900-1915	10.3	5
66	Emerging corticosteroid delivery platforms for treatment of diabetic macular edema. <i>Expert Opinion on Emerging Drugs</i> , 2020 , 25, 383-394	3.7	1
65	Multicolor imaging in macular telangiectasia-a comparison with fundus autofluorescence. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2020 , 258, 2379-2387	3.8	7
64	Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab. <i>Clinical and Experimental Ophthalmology</i> , 2020 , 48, 53-60	2.4	3
63	Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. <i>Acta Ophthalmologica</i> , 2020 , 98, e217-e223	3.7	47
62	Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. <i>Acta Diabetologica</i> , 2019 , 56, 1347-1350 ²⁶	3.9	26
61	Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis. <i>Ophthalmologica</i> , 2019 , 242, 163-177	3.7	6
60	Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. <i>BMJ Open Ophthalmology</i> , 2019 , 4, e000249	3.2	20
59	Causative Pathogens of Endophthalmitis after Intravitreal Anti-VEGF Injection: An International Multicenter Study. <i>Ophthalmologica</i> , 2019 , 241, 211-219	3.7	10
58	Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. <i>Acta Diabetologica</i> , 2019 , 56, 777-784	3.9	9
57	Development of New Proliferative Diabetic Retinopathy in the BEVORDEX Trial. <i>Ophthalmology Retina</i> , 2019 , 3, 286-287	3.8	2
56	Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab. <i>Clinical and Experimental Ophthalmology</i> , 2019 , 47, 287-289	2.4	2
55	Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. <i>Ophthalmology Retina</i> , 2019 , 3, 623-628	3.8	14
54	Steroids for Diabetic Macular Oedema [A Brief Review of the Data. <i>European Ophthalmic Review</i> , 2019 , 13, 44	0.6	0
53	Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusions: A Systematic Review and Meta-Analysis. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019 , 8, 236-246	3.5	2
52	Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2019 , 126, 64-74	7.3	15

51	Acute retinopathy and loss of vision following routine cataract surgery. <i>Clinical and Experimental Ophthalmology</i> , 2019 , 47, 294-296	2.4	1
50	DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. <i>Retina</i> , 2019 , 39, 44-51	3.6	99
49	Comparison of ICare tonometry to Goldmann tonometry for the measurement of intraocular pressure changes following intravitreal anti-vascular endothelial growth factor injection. <i>Clinical and Experimental Ophthalmology</i> , 2018 , 46, 821-823	2.4	2
48	Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. <i>Acta Diabetologica</i> , 2018 , 55, 789-796	3.9	60
47	Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. <i>The Cochrane Library</i> , 2018 , 4, CD011599	5.2	23
46	The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial. <i>Ophthalmology Retina</i> , 2018 , 2, 231-234	3.8	6
45	Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2018 , 102, 479-482	5.5	8
44	The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15
43	Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2017 , 101, 1329-1333	5.5	7
42	Hypertensive eye disease: a review. <i>Clinical and Experimental Ophthalmology</i> , 2017 , 45, 45-53	2.4	56
41	Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). <i>Ophthalmology</i> , 2016 , 123, 1399-401	7.3	44
40	Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A Clinical Trial Comparing Ozurdex Sustained Release Dexamethasone Intravitreal Implant and Bevacizumab Treatment for Diabetic Macular Edema 2016 , 57, 5541-5546		26
39	Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. <i>British Journal of Ophthalmology</i> , 2016 , 100, 1000-1004	5.5	24
38	Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review. <i>Clinical and Experimental Ophthalmology</i> , 2016 , 44, 335-9	2.4	4
37	Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. <i>Therapeutic Advances in Chronic Disease</i> , 2015 , 6, 234-45	4.9	21
36	Novel optical coherence tomography classification of torpedo maculopathy. <i>Clinical and Experimental Ophthalmology</i> , 2015 , 43, 342-8	2.4	39
35	Patient experiences in retinal trials: a cross-sectional study. <i>BMC Ophthalmology</i> , 2015 , 15, 80	2.3	8
34	A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. <i>Ophthalmology</i> , 2014 , 121, 2473-81	7.3	210

33	Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2014 , 92, e697-8	3.7	10
32	Retrospective analysis of the natural history and management of serpiginous choroiditis in Australia and New Zealand. <i>Clinical and Experimental Ophthalmology</i> , 2014 , 42, 656-64	2.4	3
31	Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration. <i>Retina</i> , 2014 , 34, 1774-8	3.6	32
30	Central serous chorioretinopathy: a review of epidemiology and pathophysiology. <i>Clinical and Experimental Ophthalmology</i> , 2013 , 41, 201-14	2.4	226
29	Diagnosis and interventions for central serous chorioretinopathy: review and update. <i>Clinical and Experimental Ophthalmology</i> , 2013 , 41, 187-200	2.4	57
28	Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. <i>Clinical Ophthalmology</i> , 2013 , 7, 1109-44	2.5	40
27	Clinical development of new treatments for diabetic macular oedema. <i>Australasian journal of optometry, The</i> , 2012 , 95, 297-305	2.7	2
26	A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. <i>JAMA Ophthalmology</i> , 2012 , 130, 972-9		279
25	Ockham's razor revisited: decreased visual acuity secondary to keratoconus in a patient with intracranial hypertension. <i>BMJ Case Reports</i> , 2011 , 2011,	0.9	
24	Punctate inner choroidopathy and multifocal choroiditis with panuveitis share haplotypic associations with IL10 and TNF loci 2011 , 52, 3573-81		32
23	Cytokine polymorphism in noninfectious uveitis 2010 , 51, 4133-42		35
22	Punctate inner choroidopathy: clinical features and outcomes. <i>JAMA Ophthalmology</i> , 2010 , 128, 982-7		63
21	A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. <i>Ophthalmology</i> , 2010 , 117, 1078-1086.e27-3	7.3	379
20	Ocular risk factors for age-related macular degeneration: the Los Angeles Latino Eye Study. <i>American Journal of Ophthalmology</i> , 2010 , 149, 735-40	4.9	29
19	Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. <i>Retina</i> , 2010 , 30, 781-6	3.6	60
18	Cataract surgery in high-risk age-related macular degeneration: a randomized controlled trial. <i>Clinical and Experimental Ophthalmology</i> , 2009 , 37, 570-6	2.4	33
17	Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study. <i>American Journal of Ophthalmology</i> , 2008 , 145, 308-16	4.9	53
16	Advances in the treatment of intermediate and posterior uveitis. <i>Expert Review of Ophthalmology</i> , 2008 , 3, 449-456	1.5	1

15	Update on treatments for diabetic macular edema. <i>Current Opinion in Ophthalmology</i> , 2008 , 19, 185-9	5.1	29
14	In vivo confocal microscopy and polarizing microscopy of the cornea in a patient with nephropathic cystinosis. <i>Clinical and Experimental Ophthalmology</i> , 2007 , 35, 292-3	2.4	10
13	Complicated hyphaema: think sickle. <i>Clinical and Experimental Ophthalmology</i> , 2006 , 34, 377-8	2.4	6
12	Smoking, alcohol intake, estrogen use, and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. <i>American Journal of Ophthalmology</i> , 2006 , 141, 79-87	4.9	94
11	Sociodemographic factors and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. <i>American Journal of Ophthalmology</i> , 2005 , 139, 30-8	4.9	29
10	Experience with the baerveldt glaucoma implant in the management of pediatric glaucoma. <i>American Journal of Ophthalmology</i> , 2005 , 139, 847-54	4.9	44
9	Refractive error, ocular biometry, and lens opalescence in an adult population: the Los Angeles Latino Eye Study. <i>Investigative Ophthalmology and Visual Science</i> , 2005 , 46, 4450-60		151
8	Prevalence and associations of epiretinal membranes in latinos: the Los Angeles Latino Eye Study. <i>Investigative Ophthalmology and Visual Science</i> , 2004 , 45, 1732-6		95
7	Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. <i>Ophthalmology</i> , 2004 , 111, 1288-97	7.3	135
6	Eye disease in Latinos. <i>International Ophthalmology Clinics</i> , 2003 , 43, 79-89	1.7	7
5	Asymmetric refraction in an older population: the Blue Mountains Eye Study. <i>American Journal of Ophthalmology</i> , 2003 , 136, 551-3	4.9	33
4	Five-year cumulative incidence and progression of epiretinal membranes: the Blue Mountains Eye Study. <i>Ophthalmology</i> , 2003 , 110, 34-40	7.3	209
3	Eye Disease in Latinos. <i>International Ophthalmology Clinics</i> , 2003 , 43, 79-89	1.7	
2	Talc retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2002 , 30, 432-3	2.4	5
1	Optic disc swelling in an adolescent with insulin dependent diabetes mellitus. <i>Clinical and Experimental Ophthalmology</i> , 2002 , 30, 434-6	2.4	1